An in vitro and in vivo screening showed Sym015, consisting of two humanized monoclonal antibodies directed against non-overlapping epitopes of MET, to be more effective than emibetuzumab, a monoclonal IgG4 antibody against MET currently in clinical development, in inhibiting MET-amplified tumors (as a mechanism to overcome resistance to EGFR-targeting agents in advanced NSCLC) [50]. This evidence concerns the gene MET and non-small cell lung carcinoma.